`
`First NamedInventor: 7o Be Named
`
`Confirmation No.: 7o Be Assigned
`
`Applicant: VISUS THERAPEUTICS, INC.
`
`Art Unit: To Be Assigned
`
`Application No.: 7o Be Assigned
`
`Examiner: 7o Be Assigned
`
`Filed: Herewith
`
`Atty. Docket: 4902.0120001
`
`Title: DEGRADANT COMPOUNDIN A MEDICAMENT
`
`Authorization to Treat a Reply as Incorporating an
`Extension of Time Under 37 C.E.R.§ 1.136(a)(3)
`
`Commissionerfor Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future
`
`reply that requires a petition for an extension of time underthis paragraph forits timely submission,
`
`as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent
`
`and Trademark Office is hereby authorized to charge all required extension of time fees to our
`
`Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/Marsha Rose Gillentine, Reg. No. 58,403/
`
`MarshaRose Gillentine
`Attorney for Applicant
`Registration No. 58,403
`
`Date:__October 18, 2021
`
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`17481084_1.docx
`
`